Prebiotics are non-digestible carbohydrates, often described as prebiotic fibres, that are selectively used by gut microbes to produce metabolites such as short-chain fatty acids (SCFAs). The main types of prebiotics differ by chemical structure, which changes which microbes respond, how fast fermentation happens, and the balance of SCFAs and gas produced. Below are the key categories, how inulin and FOS, GOS prebiotics, and resistant starch compare, and how to test effects before investing in clinical trials.
What are prebiotics and how do they work in the gut?
Prebiotics are substrates that escape digestion in the upper gastrointestinal tract and are selectively fermented by colonic microbes, shifting microbial activity and metabolite output. Probiotics are live microorganisms, while synbiotics combine a probiotic with a prebiotic designed to support it. Prebiotic fermentation commonly increases SCFAs, including acetate, propionate, and butyrate, which are widely used as functional readouts in preclinical R&D.
For product developers, “selective” is the key word. A prebiotic is not just “fibre”, it is a structure that certain microbes can access, often leading to targeted changes (for example, bifidogenic responses). That is why chemical identity, not just total fibre content, drives reproducibility, mechanism-of-action narratives, and regulatory-ready substantiation.
What types of prebiotics exist?
The main types of prebiotics are defined by their carbohydrate backbone and linkages. In practice, R&D teams screen across several classes because each one has a different fermentation speed, microbial selectivity, and tolerability profile.
- Inulin-type fructans (inulin and FOS): chicory root, Jerusalem artichoke, onion, garlic; common as powders.
- GOS prebiotics (galacto-oligosaccharides): produced from lactose; common in powders and syrups.
- Resistant starch: cooked and cooled potatoes/rice, green banana flour, high-amylose maize; used in powders and food matrices.
- Beta-glucans: oats, barley, some yeasts and mushrooms; used as concentrates and functional ingredients.
- Pectins: citrus peel, apple pomace; often used as fibres or extracted fractions.
- Arabinoxylans: wheat, rye, maize; includes soluble fractions and oligosaccharides.
- PHGG (partially hydrolysed guar gum): derived from guar; typically a soluble fibre powder.
- Lactulose: a synthetic disaccharide, used as a defined fermentable substrate in research contexts.
- HMOs (human milk oligosaccharides): produced via fermentation or enzymatic routes; used in specialised nutrition applications.
How do different prebiotics differ in structure and fermentation?
Prebiotics differ by chain length, branching, solubility, and glycosidic bonds, and these features largely determine fermentation rate, where fermentation is concentrated, and which taxa are favoured. Faster fermentation can increase gas and acidification earlier, while slower or more complex structures may spread fermentation across time and microbial guilds, affecting SCFA profiles.
| Prebiotic type | Typical structure feature | Common fermentation pattern (general) |
|---|---|---|
| Inulin and FOS | Fructan chains, variable DP | Often rapid, frequently bifidogenic, can be gas-associated in some microbiomes |
| GOS prebiotics | Galactose-based oligosaccharides | Often rapid and bifidogenic, useful for dose-response screening |
| Resistant starch | Granular/retrograded starch fractions | Often slower, can support butyrogenic networks via cross-feeding |
| Pectins, arabinoxylans | More complex, branched polysaccharides | Broader microbial utilisation, structure-dependent SCFA shifts |
From a development standpoint, plan to compare candidates under matched conditions and include a tolerability-oriented readout (for example, gas pressure in closed systems). Also expect inter-individual variability, as the same substrate can yield different metabolite profiles across donor microbiomes, which matters for positioning and trial design.
Which prebiotic is best for specific goals like regularity, bloating, or metabolic health?
No single prebiotic is “best” across all endpoints because outcomes depend on the target population, baseline microbiome, dose, and matrix. In R&D, it is more reliable to map a goal to a measurable preclinical endpoint, then select the prebiotic type most likely to drive that mechanism (and to check variability across donors).
- Regularity-oriented concepts: often start with well-characterised fermentable fibres such as inulin-type fructans, PHGG, or selected beta-glucans, then confirm fermentation kinetics and gas.
- Gas-sensitive concepts: prioritise candidates with slower fermentation or lower gas signatures in closed fermentation, and use stepwise dose escalation in development plans.
- Metabolic health positioning: commonly focuses on propionate and butyrate pathways, often explored with resistant starch and specific complex fibres, validated via SCFA and metabolomics panels.
For regulated or vulnerable cohorts, align decisions with clinical and regulatory teams early, and avoid extrapolating consumer guidance from preclinical signals alone.
How can prebiotic effects be tested before clinical trials?
Preclinical testing typically combines digestion simulation (when the matrix is digestible) with colonic fermentation to quantify how a candidate changes microbial metabolism. The most decision-useful designs include multiple donors, negative controls, and a dose-response, so teams can identify responders, non-responders, and a plausible mechanism before spending €500,000 to €5,000,000+ on a trial.
- In vitro fermentation: fast screening of substrates, but quality depends heavily on media, controls, and donor handling.
- Ex vivo gut models: aim to preserve community structure and function more faithfully, supporting better translation.
- Digestion to fermentation pipelines: link upper-GI processing to colonic outcomes for complex foods and formulations.
Common endpoints include SCFAs, gas, community composition, functional metabolites, and, where relevant, host-interface readouts (barrier and immune proxies). Best practice is to treat results as comparative evidence to rank candidates and refine hypotheses, not as clinical efficacy proof.
How does Cryptobiotix help with prebiotics research and development?
Cryptobiotix supports prebiotic R&D by generating decision-ready, mechanistic data on how different types of prebiotics behave across individuals, doses, and matrices using the SIFR® technology platform, with scientific rationale aligned to our scientific evidence approach and sector needs across applications.
- High-throughput ex vivo fermentation to compare inulin and FOS, GOS prebiotics, resistant starch, and complex fibres side by side
- Mechanism-of-action and dose-response outputs using SCFAs, gas, taxonomy, and metabolite profiles
- Inter-individual variability mapping to inform cohort strategy and responder hypotheses before clinical work
- Optional digestion-to-fermentation workflows for realistic testing of finished formulations and food matrices
If you want to de-risk a prebiotic pipeline with predictive preclinical evidence, contact us to discuss your target claims, cohorts, and study design.
FAQ
Are inulin and FOS the same prebiotic?
No. Both are inulin-type fructans, but FOS is typically shorter-chain, while inulin often has longer-chain fractions. That difference can change fermentation speed, microbial selectivity, and gas kinetics, which is why they should be tested as distinct ingredients in preclinical screening.
Do all prebiotic fibres increase Bifidobacterium?
No. Many prebiotics can be bifidogenic, but the effect depends on structure and the starting microbiome. Some fibres drive broader community shifts or favour other functional groups (for example, propionate-associated Bacteroidota members). Measuring species-level shifts alongside SCFAs helps avoid overgeneralising “bifidogenic” as a universal outcome.
Why does resistant starch behave differently from oligosaccharides?
Resistant starch is often a more complex, physically structured substrate (granules or retrograded starch), which can slow access and fermentation compared with soluble oligosaccharides like GOS. This can shift where and when metabolites are produced, and may support different cross-feeding networks that influence butyrate and propionate production.
